Clinical trial
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV…
NCT00470210 · Germans Trias i Pujol Hospital, Other · Completed
Key facts
| NCT number | NCT00470210 |
|---|---|
| Title | Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens |
| Official title | Efficacy and Safety of High-dose Ribavirin (1600 mg/d) Boosted With Epoetin β (450 IU/kg/wk) in HIV/HCV Coinfected Patients Not Responding to Previous Treatment Regimens |
| Lead sponsor | Germans Trias i Pujol Hospital, Other |
| Collaborators | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, HIV Infections |
| Intervention type | Drug |
| Interventions | Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week, Ribavirin (Copegus®) 1600 mg/day, Epoetin β (450 UI/kg/week) |
| Enrollment | 10 |
| Start date | May 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | May 7, 2007 |
| Last update posted | Dec 5, 2019 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: